EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Cytogenetic risk–associated outcomes of antithymocyte globulin use in HLA-matched sibling transplantation for acute myeloid leukemia

Mihee Kim, Ik-Chan Song, Seo-Yeon Ahn, Ho Cheol Jang, Jeong Suk Koh, Chang-Hoon Lee, Hyeoung-Joon Kim, Ho-Young Yhim, Jae-Sook Ahn

Annals of Hematology · 16.10.2025 · 104 (11) · 5995-6004

DOI: 10.1007/s00277-025-06608-3 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Annals of Hematology, online erschienen am 16.10.2025. Verfasst von Mihee Kim und 8 weiteren Autor:innen. Beteiligte Einrichtung: Hematology-Oncology, Chonnam National University Hwasun Hospital, Hwasun-gun, Jeollanam-do, Republic of Korea. Hauptthemen laut MEDLINE: Antilymphocyte Serum, Leukemia, Myeloid, Acute, Siblings, Hematopoietic Stem Cell Transplantation. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Health & Welfare, Republic of Korea, Chonnam National University Hwasun Hospital Institute for Biomedical Science, National Research Foundation of Korea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antithymocyte globulin (ATG) reduces chronic graft-versus-host disease (cGvHD), but concerns remain regarding relapse risk, particularly across cytogenetic risk groups. We retrospectively analyzed 148 acute myeloid leukemia (AML) patients in first remission who underwent matched sibling allogeneic hematopoietic stem cell transplantation (HSCT) across three centers. Patients received transplantation with or without ATG (2.5–5 mg/kg) and were stratified by cytogenetic risk (intermediate, n = 128; adverse, n = 20). Propensity score matching and inverse probability of treatment weighting were applied to adjust for baseline imbalances. After a median follow-up of 91 months, ATG use ( n = 96) reduced the incidence of cGvHD (HR 0.43; 95% CI 0.26–0.72; p = 0.001) and improved cGvHD-free relapse-free survival (cGRFS; HR 0.61; 95% CI 0.40–0.93; p = 0.022). No significant differences were observed in overall survival, event-free survival (EFS), relapse, or non-relapse mortality. A significant interaction between ATG and cytogenetic risk ( p = 0.025) indicated differential effects by risk profiles. In subgroup analyses, intermediate-risk patients derived consistent benefit, whereas adverse-risk patients (ATG n = 12; non-ATG n = 8) showed higher relapse and inferior EFS. With respect to dose, both 2.5 and 5 mg/kg reduced cGvHD relative to non-ATG; exploratory analyses suggested that 2.5 mg/kg may provide adequate prophylaxis without excess relapse, although statistical power was limited. In conclusion, ATG was associated with reduced cGvHD and improved cGRFS in HSCT for AML, with benefit mainly in intermediate-risk patients. Its use in adverse-risk AML warrants caution, as it may be associated with higher relapse.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antilymphocyte SerumLeukemia, Myeloid, AcuteSiblingsHematopoietic Stem Cell TransplantationGraft vs Host DiseaseHumansMaleFemaleMiddle AgedAdultRetrospective StudiesAdolescentYoung AdultRisk FactorsAgedTreatment OutcomeDisease-Free SurvivalFollow-Up Studies

Stichwörter der Autor:innen

Acute myeloid leukemiaAntithymocyte globulinChronic graft-versus-host disease-free relapse-free survivalGraft-versus-host disease

Substanzen

Antilymphocyte Serum

Autor:innen und Institutionen

  • Hematology-Oncology, Chonnam National University Hwasun Hospital, Hwasun-gun, Jeollanam-do, Republic of Korea.
  • Genomic Research Center for Hematopoietic Diseases, Chonnam National University Hwasun Hospital, Hwasun-gun, Jeollanam-do, Republic of Korea.
  • Division of Hematology/Oncology, Department of Internal Medicine, Chungnam National University College of Medicine, Daejeon, Republic of Korea.
  • Hematology-Oncology, Department of Internal Medicine, Jeonbuk National University Medical School, Jeonju, Republic of Korea.
  • Hematology-Oncology, Department of Internal Medicine, Jeonbuk National University Medical School, Jeonju, Republic of Korea. yhimhy@jbnu.ac.kr.
  • Department of Internal Medicine, Jeonbuk National University Medical School, 20, Geonjiro Deokjin-gu, Jeonju-si, Jeollabuk-do, 54907, Republic of Korea. yhimhy@jbnu.ac.kr.

Förderung

  • Ministry of Health & Welfare, Republic of Korea
  • Chonnam National University Hwasun Hospital Institute for Biomedical Science
  • National Research Foundation of Korea
  • Korea Health Industry Development Institute

Zitieren

APA

Kim, M., Song, I. C., Ahn, S. Y., Jang, H. C., Koh, J. S., Lee, C. H., Kim, H. J., Yhim, H. Y., & Ahn, J. S. (2025). Cytogenetic risk–associated outcomes of antithymocyte globulin use in HLA-matched sibling transplantation for acute myeloid leukemia. Annals of Hematology, 104(11), 5995-6004. https://doi.org/10.1007/s00277-025-06608-3

Vancouver

Kim M, Song IC, Ahn SY, Jang HC, Koh JS, Lee CH, et al. Cytogenetic risk–associated outcomes of antithymocyte globulin use in HLA-matched sibling transplantation for acute myeloid leukemia. Annals of Hematology. 2025;104(11):5995-6004. doi:10.1007/s00277-025-06608-3

BibTeX
@article{Kim2025,
  author = {Kim, Mihee and Song, Ik-Chan and Ahn, Seo-Yeon and Jang, Ho Cheol and Koh, Jeong Suk and Lee, Chang-Hoon and Kim, Hyeoung-Joon and Yhim, Ho-Young and Ahn, Jae-Sook},
  title = {Cytogenetic risk–associated outcomes of antithymocyte globulin use in HLA-matched sibling transplantation for acute myeloid leukemia},
  journal = {Annals of Hematology},
  year = {2025},
  volume = {104},
  number = {11},
  pages = {5995--6004},
  doi = {10.1007/s00277-025-06608-3}
}
Kostenlos starten →